Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

CIT is not being developed anywhere. In 2010 there was some press about CIT and NuVax, but NuVax is currently dormant, with no money and no employees.

The FACTS are here in the SEC filing if anyone is interested in FACTS:

https://www.sec.gov/Archives/edgar/data/838879/000114420412037312/v316641_10k.htm

Radient wrote off CIT as worthless on Dec 31, 2010. They then tried to develop Dr. Chang's newer technology from the University of Florida. When they got more financing in 2011 they did not spend any of it on CIT, and when they ran out of money in 2011 NuVax ceased operations.

Page 11 of the 10K:

"Due to the following conditions at December 31, 2010, we decided to impair the remaining balance of our CIT asset:
· Lack of any potential future revenue;
· Lack of future cash flows;
· High cost of future clinical studies; and
· Limited time remaining on the patent."

"In January 2011, NuVax signed four exclusive license agreements with the University of Florida Research Foundation, Inc. (“UFRF”), for the development and marketing of a cancer therapeutic product developed by the UFRF. In July 2011, the UFRF terminated the agreements due to lack of funding.

On August 29, 2011, due to lack of funding and activity, Umesh Batia resigned as CEO and Director of NuVax. As of the date of this report, we have not generated any revenues and incurred license termination fees expenses for NuVax. Until we can complete funding for NuVax, we will continue to have minimal activity in NuVax."

No news since then means NuVax is still dormant. To suggest that "lack of news" means NuVax is secretly operating again is absurd.

As for SRL: SRL never had an agreement or license with Radient or AMDL. There is no evidence that SRL is doing anything with CIT, DR-70, onko-sure, or NuVax. SRL sold some DR-70 tests they acquired from Guar Diagno, selling them at half price of $44 USD, but that supply ran out long ago and SRL did not order more tests -- instead, they stopped selling the tests.